Membranous Glomerulonephritis

Back

Practice Essentials

Membranous nephropathy (MGN) is the most common cause of nephrotic syndrome in the adult population, but also occurs in children.[1] Approximately 80% of MGN cases are idiopathic; the remainder are secondary (eg, to malignancy, infectious disease, or an autoimmune disorder). Idiopathic and secondary MGN can be distinguished by clinical, laboratory, and histological features (see Presentation and Workup).

In secondary MGN, successful treatment of the underlying cause may be curative. Patients with idiopathic MGN may experience spontaneous remission, persistent proteinuria of variable degree, or progression to kidney failure. Immunosuppressive therapy may be appropriate for selected patients with idiopathic MGN who are at elevated risk for kidney dysfunction (see Treatment and Medication).[2]

Pathophysiology

Membranous nephropathy is an autoimmune disorder in which immune complexes deposit along the subepithelial region of the glomerular basement membrane. Antigen-antibody complexes can develop by the production of immune complexes in situ or by deposition of circulating complexes. In the Heymann nephritis model of experimental membranous nephropathy in rats, the intrinsic antigen is a glycoprotein, megalin, synthesized by the glomerular visceral epithelial cells; however, megalin is not present in the human glomerulus.[3]

M-type phospholipase A2 receptor (PLA2R) has been identified as the major target antigen in idiopathic membranous nephropathy in adults. Circulating autoantibodies against PLA2R have been found in 70-80% of patients with idiopathic membranous nephropathy.[4, 5] Anti-PLA2R antibodies are typically not found in patients with secondary membranous nephropathy.[4] Anti-PLA2R antibodies have been found in patients with viral infections (eg, hepatitis B, hepatitis C, HIV), but those patients may have had coincidental primary membranous nephropathy.[6] Detection of anti-PLA2R antibodies in glomeruli but not in liver parenchyma is a common finding in phatients with membranous nephropathy associated with autoimmune liver disease, suggesting that these autoantibodies are not exclusive to idiopathic membranous nephropathy.[7]

Another minor antigen is thrombospondin type 1 domain–containing 7A (THSD7A). Patients who are positive for anti-THSD7A autoantibodies represent a distinct subgroup with this disease and make up approximately 2.5 to 5% of adultts with idiopathic membranous nephropathy.[8, 9] Hoxha et al reported expression of THSD7A in a gallbladder carcinoma, in a patient who developed membranous nephropathy with anti-THSD7A antibodies, and subsequently found anti-THSD7A antibodies in six other patients with membranous nephropathy and malignant tumors, suggesting that THSD7A production by malignancies is a possible mechanism for membranous nephropathy.[10]

Other target antigens detected in patients with membranous nephropathy include the following[11] :

Debiec et al reported that four of nine patients with childhood membranous nephropathy had high levels of circulating anti–bovine serum albumin antibodies and circulating cationic bovine serum albumin. Bovine serum albumin was also seen in immune deposits. It is present in cow's milk and beef protein and can escape the intestinal barrier and cause antibody formation. Its cationic nature allows binding to the anionic glomerular capillary wall with resultant immune complex formation, a parallel to experimental models. This possible environmental trigger could lead to childhood membranous nephropathy, and improvement may be found by eliminating it from the diet.[12]

Neutral endopeptidase, a podocyte antigen that can digest biologically active peptides, was identified as the target antigen in a subset of patients with antenatal membranous nephropathy. In these cases, the patients' mothers carried a mutation that rendered them deficient in neutral endopeptidase and they had undergone alloimmunization due to exposure to paternal neutral endopeptidase during pregnancy.[13]

Many of the antigens associated with secondary membranous nephropathy are also not known. However, hepatitis B surface antigens and hepatitis E antigens have been identified in immune deposits, as have thyroid antigens in patients with thyroiditis.

The complement membrane attack complex (C5b-9) triggers the biosynthesis of oxygen radical–producing enzymes within the glomerular epithelial cells. The finding of urinary C5b-9 has been suggested as a diagnostic test for following disease activity.[14]

C5b-9 in sublytic quantities stimulates podocytes to produce proteases, oxidants, prostanoids, extracellular matrix components, and cytokines, including transforming growth factor-beta (TGF-beta). C5b-9 also causes alterations of the cytoskeleton that lead to an abnormal distribution of slit diaphragm protein and detachment of viable podocytes that are shed into the Bowman space. These events result in disruption of the functional integrity of the glomerular basement membrane and the protein filtration barrier of podocytes with subsequent development of massive proteinuria.

A study by Kuroki et al found that the immune response in idiopathic membranous nephropathy is characterized by alteration of T-cell function to produce Th2 cytokines and increased production of IgG4 by B cells in response to those cytokines.[15] A study by Cohen et al pointed to the involvement of B cells in the pathogenesis of membranous nephropathy, possibly as antigen-presenting cells. These authors measured the interstitial expression of CD20 messenger RNA (mRNA) in patients with membranous nephropathy and in control subjects with other kidney diseases. CD20 mRNA expression was significantly higher in patients with membranous nephropathy than in control subjects. B-cell infiltration was confirmed by immunohistochemistry.[16]

Epidemiology

Frequency

United States

The annual incidence of membranous nephropathy in the United States is estimated at about 12 cases per million population. Membranous nephropathy accounts for approximately 1.9 cases of end-stage kidney disease (ESKD) per million population per year in the US; hence, because only 10-20% of patients with primary membranous nephropathy progress to ESKD, the actual incidence may be as high as 20 cases per million population per year.[6]

Primary membranous nephropathy comprises about 80% of cases, while the remainder are secondary to other systemic diseases or exposures (eg, malignancy, infectious disease, autoimmune disorders).[6, 11, 13] The relative distribution of pathologic causes of nephrotic syndrome varies considerably among various centers, based on population and referral pattern factors.

In the pediatric population, membranous nephropathy is rare but serious. Membranous nephropathy is found in 1-7% of kidney biopsies in children.[6] Long-term prognosis is guarded because approximately 50% of patients may have evidence of progressive kidney disease.[17]

International

Internationally, the frequency is the same as in the United States, although it is influenced by the prevalence of secondary causes. These include infectious disease such as malaria in Africa and hepatitis B in parts of Asia.[18]

Mortality/Morbidity

The course is variable, and patients may be divided into 3 groups of approximately equal size (ie, "rule of thirds").

Patients in the first and second category die from nonrenal causes.

Race-, sex-, and age-related demographics

Epidemiologic features include the following[13, 18, 6] :

Prognosis

Overall, patients with primary membranous nephropathy have a good prognosis. Approximately 30% of patients undergo spontaneous remission and another 30% have variable degrees of proteinuria but stable kidney function for many years. However, about 30% progress to kidney failure. Factors at presentation that have been associated with a poor prognosis include male gender, older age, high levels of proteinuria, and abnormal kidney function.[18]

Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using clinical and laboratory criteria for assessing risk of progressive loss of kidney function in patients with membranous nephropathy. On the basis of those criteria, patients can be classified into one of four risk groups (low, moderate, high, or very high), which serves as a guide for therapy.[19]

Criteria for low risk are as follows:

Criteria for moderate risk are as follows:

Criteria for high risk are as follows:

Criteria for very high risk are as follows:

 

History

See the list below:

Physical

See the list below:

Causes

Causes of membranous nephropathy can be idiopathic or secondary. Often, distinguishing between idiopathic and secondary causes is not possible based on clinical evidence alone. In secondary membranous nephropathy, such as lupus and hepatitis, concomitant mesangial or subendothelial deposits may be present. De novo membranous glomerulopathy (DNMG) can develop post transplant. This can be in the context of a donor-specific alloantibody (DSA) directed against HLA DQ7.[20]

Laboratory Studies

Laboratory studies in patients with suspected membranous nephropathy are intended to evaluate the status of the kidneys and to search for an underlying cause. Tests include the following:

Measurement of antibodies against the M-type phospholipase A2 receptor (anti-PLA2R antibodies) is used for diagnosis, determining prognosis, and monitoring response to therapy in membranous nephropathy.[1, 19, 21] Anti-PLA2R antibodies have high specificity (close to 100%) and sensitivity (70-80%) for diagnosis.[22] Patients with absent or low anti-PLA2R levels are more likely to undergo spontaneous remission, whereas patients with high baseline anti-PLA2R antibody levels tend to achieve remission of proteinuria significantly later than those with low baseline levels, and are at greater risk of failing to achieve remission.[23]

An exhaustive workup for malignancy is not recommended because most cases of membranous nephropathy are not associated with cancer. However, because some increase in the rate of occult malignancy is recognized in patients with newly diagnosed membranous nephropathy, (1) ensure that age-appropriate health screening (eg, mammography, sigmoidoscopy) has been performed, and (2) investigate any clues from the initial patient history and physical examination.

Procedures

Although Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize that kidney biopsy remains the “gold standard” for the diagnosis of glomerular diseases, the 2021 KDIGO guidelines dropped the requirement of kidney biopsy for confirmation of the diagnosis of membranous nephropathy in patients who have nephrotic syndrome and a positive PLA2R antibody test.  However, the guidelines stress that a kidney biopsy can provide important additional information in these cases.[19]

Histologic Findings

Pathologic features can be observed using light microscopy, immunofluorescence microscopy, and electron microscopy.

Approach Considerations

In secondary membranous nephropathy, successful treatment of the underlying cause may be curative. For example, in hepatitis-associated membranous nephropathy, antivirals may be useful.[24, 25]

Symptomatic treatment includes the following:

Nonsteroidal anti-inflammatory drugs (NSAIDs) can help to decrease the proteinuria; however, NSAIDs have been largely supplanted by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). ACE inhibitors decrease proteinuria and control hypertension; use ARBs for patients intolerant of ACE inhibitors.

Routine anticoagulation is controversial. However, the risk of renal vein thrombosis and other deep vein thromboses is significant, and the clinician must be vigilant in monitoring for signs of venous thromboembolism (VTE). Once VTE is found, anticoagulation is generally continued indefinitely. In a study of membranous nephropathy, the risk of developing VTE increased 3.9-fold with a reduction in serum albumin below the threshhold of 2.8 g/dL and 5.8-fold with a serum albumin of less than 2.2 g/dL.[26]

Treatment is guided by risk category (see Overview/Prognosis). Do not treat patients with asymptomatic nonnephrotic proteinuria with immunosuppressives. Patients who are asymptomatic and nephrotic may undergo remission, particularly if they have normal kidney function and an early lesion. They may also be observed.

Therapy with immunosuppressive agents (see Medication) is indicated in those patients who have the following:

Kidney transplantation is indicated if the patient progresses to end-stage kidney disease. Some risk of recurrence in the allograft is recognized.

Medication Summary

Historically, immunosuppressive therapy for membranous nephropathy has consisted principally of alkylating agents (ie, chlorambucil or cyclophosphamide) combined with corticosteroids. Alternatively, calcineurin inhibitors (CNIs; cyclosporine or tacrolimus) have been used.[27, 21]

Currently, however, rituximab (a monoclonal antibody against the CD20 antigen of B lymphocytes) is considered the first-line agent for membranous nephropathy.[21] In the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, treatment with cyclophosphamide and corticosteroids is recommended only for patients at very high risk for kidney failure (eg, those with life-threatening nephrotic syndrome)—and even in those cases, rituximab might be offered to patients with intolerance of or contraindications to cyclophosphamide.[19]

The KDIGO recommendations apply only to adult patients. The guidelines note that there is no evidence to guide management of the very rare cases of membranous nephropathy in children, and instead recommend referring pediatric patients to an expert center.[19]

For adult patients at high risk, KDIGO guidelines recommend rituximab, with cyclophosphamide plus corticosteroids or a calcineurin inhibitor plus rituximab as alternatives. For those at moderate risk, KDIGO guidelines recommend a wait-and-see approach, with rituximab or a calcineurin inhibitor plus rituximab as alternatives.[19]

Rituximab has become the first-line agent in this setting due to its favorable safety profile and demonstrated efficacy. In several studies, including 3 randomized controlled trials, approximately two-thirds of patients treated with rituximab achieved complete or partial remission of proteinuria.[28]

A variety of dosing regimens have been used in studies of rituximab for membranous nephropathy. These have included 375 mg/m2 given in a single dose or weekly for up to four doses, and two doses of 1000 mg given 2 weeks apart. In patients who achieve partial remission, a second dosing has been given after 6 months.[28, 29] Titration of rituximab to circulating CD20 B cell counts may improve safety by avoiding hypersensitivity. It also may limit the costs of treatment while achieving similar results.[30]

To evaluate treatment response and guide therapy, anti-PLA2R antibody levels should be measured every 3 to 6 months, with the shorter interval used in patients with high baseline levels. In treatment-responsive cases, reduction in antibody titers precede decreases in proteinuria. Remission of proteinuria tends to occur significantly faster in patients with low baseline anti-PLA2R antibody levels than in patients with high levels.[23] Disappearance of anti-PLA2R antibodies precedes clinical remission and indicates that additional therapy will not be needed.[19]

Cyclophosphamide is given in alternating months with corticosteroids over 6 months, with adjustment of the cyclophosphamide dose according to the patient's age and estimated glomerular filtration rate. The goals are to achieve both total remission and preservation of kidney function. Due to the risk of malignancy, the cumulative dose of cyclophosphamide should not exceed 36 g. In patients wishing to preserve fertility, the cumulative dose of cyclophosphamide should not exceed 10 g.[19]

Cyclical corticosteroid/alkylating agent therapy for idiopathic membranous nephropathy (IMN) (the Ponticelli regimen) is as follows:

Monitor every 2 weeks for 2 months, then every month for 6 months, with serum creatinine, urinary protein excretion, serum albumin, and white blood cell count. If the total leukocyte count falls to less than 3500/µL, hold chlorambucil or cyclophosphamide until recovery to 44000/µL.

KDIGO guidelines suggest conservative management for at least 6 months following the completion of this regimen before labelling the case as a treatment failure.[19]

Treatment with a CNI can be used in patients with a normal estimated glomerular filtration rate (eGFR) who are at moderate or high risk of progression of kidney dysfunction. CNIs have better short-term efficacy and safety than alkylating agents, but relapse rates of 40-50% after discontinuation.[28] In patients at high risk for progression, the addition of rituximab after 6 months of treatment is advised, except possibly in patients with documented disappearance of anti-PLA2R antibodies.[19]

CNIs should be discontinued in patients who do not achieve complete or partial remission after 6 months of treatment. The dosage should be reduced at intervals of 4-8 weeks to a level of about 50% of the starting dosage once remission is maintained and continued for at least 12 months. Regimens are as follows:

KDIGO recommendations for second-line therapy depend on whether the eGFR is stable or decreasing. Patients with a stable eGFR whose disease is resistant to rituximab can be treated with the addition of a CNI to rituximab; those with disease resistant to a CNI or cyclophosphamide plus corticosteroids can be treated with rituximab. If no response occurs after 3 months, third-line therapy is with cyclophosphamide plus corticosteroids. Patients with a decreasing eGFR should be treated with cyclophosphamide plus corticosteroids.[19]  

Patients whose disease is resistant to rituximab and cyclophosphamide plus corticosteroids should be referred to an expert center. Such centers may recommend experimental therapies (eg, bortezomib, anti-CD38 therapy [eg, daratumumab], belimumab) or a higher dose of conventional immunosuppressive therapy.[19]

In patients with idiopathic membranous nephropathy, histology findings including interstitial fibrosis, tubular atrophy, and vascular sclerosis have been associated with the risk of kidney failure, but it remains uncertain whether they are independent of the clinical variables at the time of biopsy, predict rate of progression, or should guide therapy. Although these histologic features were associated with a reduced renal survival rate, they did not predict this outcome independently of the baseline clinical variables, nor did they correlate with the rate of decline in function.[31]

Furosemide (Lasix)

Clinical Context:  Has a potent diuretic effect because it blocks sodium reabsorption in the thick ascending loop of Henle.

Class Summary

Used to control volume overload.

Simvastatin (Zocor)

Clinical Context:  Decreases intracellular cholesterol pools and increases LDL receptors, which causes a decrease in LDL-C.

Atorvastatin (Lipitor)

Clinical Context:  Inhibits 3-hydroxy-3-methylglutaryl coenzyme A, which, in turn, inhibits cholesterol synthesis and increases cholesterol metabolism.

Class Summary

Decrease the increased cholesterol associated with nephrotic syndrome.

Prednisone (Deltasone, Meticorten, Orasone, Sterapred)

Clinical Context:  Exerts an anti-inflammatory effect via the inhibition of inflammatory mediator gene transcription.

Methylprednisolone (Adlone, Medrol, Solu-Medrol)

Clinical Context:  Exerts an anti-inflammatory effect via inhibition of inflammatory mediator gene transcription.

Cyclophosphamide (Cytoxan, Neosar)

Clinical Context:  Used for remission of nephrotic syndrome. Interferes with normal function of DNA by alkylation and cross-linking the strands of DNA and by possible protein modification.

Chlorambucil (Leukeran)

Clinical Context:  For remission of proteinuria; given with prednisone (0.5 mg/kg/d) every other month. Steroids are given as 1 g methylprednisolone IV for 3 d. Interferes with DNA replication and RNA transcription by alkylation and cross-linking the strands of DNA

Class Summary

Induce remission of proteinuria.

Cyclosporine A (Sandimmune)

Clinical Context:  Inhibits production and release of IL-2, leading to inhibition of IL-2–mediated activation of T lymphocytes.

Class Summary

For remission of nephrotic syndrome.

Lisinopril (Zestril, Prinivil)

Clinical Context:  Inhibition of ACE leads to decreased plasma angiotensin II, which, in turn, leads to decreased vasopressor activity and decreased aldosterone secretion. ACE inhibitors minimize secondary intraglomerular hypertension and hypertrophy, leading to decreased proteinuria in idiopathic membranous nephropathy.

Enalapril (Vasotec)

Clinical Context:  Competitive inhibitor of ACE. Reduces angiotensin II levels, decreasing aldosterone secretion.

Class Summary

Control blood pressure and proteinuria.

Ibuprofen (Motrin, Ibuprin)

Clinical Context:  Exerts its effects by inhibiting both constitutive and inducible isoforms of cyclooxygenase, which produces a mild-to-moderate anti-inflammatory and analgesic effect. NSAIDs decrease intraglomerular pressure and decrease proteinuria.

Naproxen (Anaprox, Naprelan, Naprosyn)

Clinical Context:  For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

Ketoprofen (Actron, Orudis, Oruvail)

Clinical Context:  For relief of mild to moderate pain and inflammation.

Small doses are initially indicated in small and elderly patients and in those with renal or liver disease. Doses >75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response.

Class Summary

Used to decrease proteinuria.

Further Outpatient Care

Management is on an outpatient basis, with emphasis on controlling blood pressure. Considerations include the following:

Complications

See the list below:

Prognosis

See the list below:

Patient Education

See the list below:

What is membranous nephropathy (MGN)?What is the pathophysiology of membranous nephropathy (MGN)?What are the racial predilections of membranous nephropathy (MGN)?What are the sexual predilections of membranous nephropathy (MGN)?Which age groups have the highest prevalence of membranous nephropathy (MGN)?What is the US prevalence of membranous nephropathy (MGN)?What is the global prevalence of membranous nephropathy (MGN)?What is the mortality and morbidity associated with membranous nephropathy (MGN)?Which clinical history findings are characteristic of membranous nephropathy (MGN)?Which physical exam findings are characteristic of membranous nephropathy (MGN)?What causes membranous nephropathy (MGN)?What are the differential diagnoses for Membranous Glomerulonephritis?Which lab tests are performed in the workup of membranous nephropathy (MGN)?Which imaging studies are performed in the workup of membranous nephropathy (MGN)?What is the role of biopsy in the workup of membranous nephropathy (MGN)?Which histologic findings are characteristic of membranous nephropathy (MGN)?What is the role of anti-PLA2R antibody testing in the workup of membranous nephropathy (MGN)?How is membranous nephropathy (MGN) treated?What is the role of kidney transplantation in the treatment of membranous nephropathy (MGN)?Which dietary modifications are used in the treatment of membranous nephropathy (MGN)?Which activity modifications are used in the treatment of membranous nephropathy (MGN)?Which medications are used in the treatment of membranous nephropathy (MGN)?Which medications in the drug class Nonsteroidal anti-inflammatory drugs are used in the treatment of Membranous Glomerulonephritis?Which medications in the drug class Angiotensin-converting enzyme inhibitors are used in the treatment of Membranous Glomerulonephritis?Which medications in the drug class Immunosuppressant agents are used in the treatment of Membranous Glomerulonephritis?Which medications in the drug class Corticosteroids are used in the treatment of Membranous Glomerulonephritis?Which medications in the drug class Hepatic 3-methylglutaryl coenzyme A reductase inhibitors are used in the treatment of Membranous Glomerulonephritis?Which medications in the drug class Diuretics are used in the treatment of Membranous Glomerulonephritis?What is included in the long-term monitoring in patients with membranous nephropathy (MGN)?What are the possible complications of membranous nephropathy (MGN)?What is the prognosis of membranous nephropathy (MGN)?

Author

Abeera Mansur, MD, Consultant Nephrologist, Doctors Hospital and Medical Center, Pakistan; Nephrologist, CHI Health Good Samaritan of Kearney, Nebraska

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ajay K Singh, MB, MRCP, MBA, Associate Professor of Medicine, Harvard Medical School; Director of Dialysis, Renal Division, Brigham and Women's Hospital; Director, Brigham/Falkner Dialysis Unit, Faulkner Hospital

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FASN, Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

James H Sondheimer, MD, FACP, FASN, Professor of Medicine, Nephrology and Hypertension, Department of Medicine, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

References

  1. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021 Sep 30. 7 (1):69. [View Abstract]
  2. Tran TH, J Hughes G, Greenfeld C, Pham JT. Overview of current and alternative therapies for idiopathic membranous nephropathy. Pharmacotherapy. 2015 Apr. 35 (4):396-411. [View Abstract]
  3. Ronco P, Debiec H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin Immunopathol. 2007 Nov. 29 (4):445-58. [View Abstract]
  4. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009 Jul 2. 361(1):11-21. [View Abstract]
  5. Reinhard L, Zahner G, Menzel S, Koch-Nolte F, Stahl RAK, Hoxha E. Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy. J Am Soc Nephrol. 2020 Jan. 31 (1):197-207. [View Abstract]
  6. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun 7. 12 (6):983-997. [View Abstract]
  7. Dauvergne M, Moktefi A, Rabant M, et al. Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases. Medicine (Baltimore). 2015 Jul. 94 (30):e1243. [View Abstract]
  8. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014 Dec 11. 371 (24):2277-87. [View Abstract]
  9. Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLoS One. 2015. 10 (9):e0138841. [View Abstract]
  10. Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016 May 19. 374 (20):1995-6. [View Abstract]
  11. Sethi S. New 'Antigens' in Membranous Nephropathy. J Am Soc Nephrol. 2021 Feb. 32 (2):268-278. [View Abstract]
  12. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011 Jun 2. 364(22):2101-10. [View Abstract]
  13. Ronco P, Debiec H. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015 Nov. 68 (1):57-62. [View Abstract]
  14. Coupes B, Brenchley PE, Short CD, et al. Clinical aspects of C3dg and C5b-9 in human membranous nephropathy. Nephrol Dial Transplant. 1992. 7 Suppl 1:32-4. [View Abstract]
  15. Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005 Jul. 68(1):302-10. [View Abstract]
  16. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol. 2005 May-Jun. 18 (3):328-33. [View Abstract]
  17. Chen A, Frank R, Vento S, et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol. 2007 Aug 6. 8:11. [View Abstract]
  18. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001 May. 59 (5):1983-94. [View Abstract]
  19. [Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct. 100 (4S):S1-S276. [View Abstract]
  20. El Kossi M, Harmer A, Goodwin J, et al. De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant. 2008 Jan-Feb. 22(1):124-7. [View Abstract]
  21. Alsharhan L, Beck LH Jr. Membranous Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021 Mar. 77 (3):440-453. [View Abstract]
  22. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015 May 16. 385 (9981):1983-92. [View Abstract]
  23. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014 Jun. 25 (6):1357-66. [View Abstract]
  24. Chuang TW, Hung CH, Huang SC, et al. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc. 2007 Oct. 106(10):869-73. [View Abstract]
  25. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int. 1995 Jan. 47(1):225-30. [View Abstract]
  26. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012 Jan. 7(1):43-51. [View Abstract]
  27. Chen Y, Schieppati A, Chen X, Cai G, Zamora J, Giuliano GA, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014 Oct 16. CD004293. [View Abstract]
  28. Gauckler P, et al; RITERM study group. Rituximab in Membranous Nephropathy. Kidney Int Rep. 2021 Apr. 6 (4):881-893. [View Abstract]
  29. Fervenza FC, et al; MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019 Jul 4. 381 (1):36-46. [View Abstract]
  30. Cravedi P, Ruggenenti P, Sghirlanzoni MC, et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007 Sep. 2(5):932-7. [View Abstract]
  31. Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006 May. 69(9):1641-8. [View Abstract]